Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the<a href="https://solaci.org/en/2023/04/17/clinical-impact-of-coronary-artery-disease-on-results-after-tavr/" title="Read more" >...</a>
ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes
At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical risk. The current ACC and AHA guidelines recommend that a Heart Team make the decision for 65 to 80-year-old patients with aortic stenosis. In low risk patients, fast recovery and short term benefits of TAVR should be weighed<a href="https://solaci.org/en/2023/03/08/acc-2023-tavr-in-low-risk-patients-3-year-outcomes/" title="Read more" >...</a>
Real-World Results of Different Devices for TAVR
Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others. This multicenter<a href="https://solaci.org/en/2023/01/04/real-world-results-of-different-devices-for-tavr/" title="Read more" >...</a>
We Should Treat Significant Stable CAD in Patients Undergoing TAVR
Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases. When we decide to treat aortic disease using surgery, it has been established we should also treat heart disease. However, when using transcatheter aortic valve replacement (TAVR), this is still unclear, given that in many occasions we see stable lesions<a href="https://solaci.org/en/2022/12/30/we-should-treat-significant-stable-cad-in-patients-undergoing-tavr/" title="Read more" >...</a>
Is There any Difference between Modern Valves and Self and Balloon Expandable Valves?
At present TAVR is a valid alternative to treat different risk groups of patients with severe aortic stenosis. Among the different valves, there are two types, the self-expanding (SEV) and the balloon expandable (BEV) valves, that are the most implanted and the most researched by randomized studies across different risk groups. There are different generations<a href="https://solaci.org/en/2022/12/16/is-there-any-difference-between-modern-valves-and-self-and-balloon-expandable-valves/" title="Read more" >...</a>
SURTAVI at 5 Years
Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280 patients and an 8 year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>
Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?
TAVR has long been an effective strategy to treat aortic stenosis. However, ventricular damage starts further before symptom onset, also affecting the left ventricle, pulmonary vessels, the right ventricle, the tricuspid valve, and the right atrium. It increases arterial afterload and uncouples the right ventricle and the pulmonary artery, defined by transthoracic echocardiogram as the relationship<a href="https://solaci.org/en/2022/09/30/is-right-ventricle-pulmonary-artery-rv-pa-coupling-important-in-low-risk-tavr/" title="Read more" >...</a>
TCT 2022 | PROTECTED TAVR
Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that<a href="https://solaci.org/en/2022/09/21/tct-2022-protected-tavr-3/" title="Read more" >...</a>
Apixaban and Valve Thrombosis after TAVR
TAVR has been associated with early valve thrombosis, characterized by thrombus formation in the prosthetic valve with or without valve dysfunction. This dysfunction is related to leaflet thickening and reduced motion, reduced effective orifice area, or increased transvalvular gradient. A multidetector CT scan allows the dynamic assessment of valves and ruling out fibrosis vs. thrombosis. <a href="https://solaci.org/en/2022/09/14/apixaban-and-valve-thrombosis-after-tavr/" title="Read more" >...</a>
TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?
Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising. TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>